AlzeCure Pharma logo

Loading..
Svenska
Svenska
  • Home
  • About us
    About us
      • AlzeCure Pharma in brief
      • Mission, vision & strategy
      • A word from the CEO
      • Organization
        • Management team
        • Board of directors
        • Founders
        • Scientific advisors
        • Collaborations and Partnership
      • History
      • Career
        • Open positions
  • Research & development
    Research & development
      • Project portfolio
      • NeuroRestore
      • Alzstatin
      • Alzheimer’s disease
      • Painless
        • ACD440
        • TrkA-NAM
      • Pain
      • Small molecules
      • Publications
  • Governance
    Governance
      • Corporate Governance Reports
      • General meeting
        • General meetings
      • Nomination Committee
      • Board of directors
      • Management team
      • Remuneration
      • Auditors
      • Articles of association
  • Investors
    Investors
      • Rights Issue 2022
      • AlzeCure Pharma on First North Premier Growth Market
        • Certified Adviser
        • Listing prospectus
      • The share
        • Trading information
        • Sharecapital development
        • Dividend policy
        • Ownership structure
        • Insiders
        • Analyst Coverage
      • Financial reports
      • Financial calendar
      • Presentations and Interviews
      • Subscribe
      • Contact
  • Media
    Media
      • Press releases
      • Presentations and Interviews
      • Video gallery
      • Image bank
        • Board of directors
        • Management
        • Founders
        • Logotype
      • Financial calendar
      • Subscribe
      • Contact
  • Contact
    Contact
      • Office
      • Investors
      • Media

Press releases

All pressreleases
  • Regulatory press releases
  • Other press releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • All years
May 10, 2022

AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference

May 5, 2022

AlzeCure publishes its interim report for January – March 2022

April 22, 2022

AlzeCure publishes new data on Alzstatin from Alzheimer conference

April 21, 2022

AlzeCure publishes new data on NeuroRestore and ACD856 from Alzheimer’s conference

April 13, 2022

AlzeCure’s rights issue is registered and the trading in Paid Subscription Shares ceases

April 11, 2022

AlzeCure carries out a set-off issue in connection with ACD440 entering phase II and Acturum Life investing in the company

April 6, 2022

AlzeCure Pharma publishes its Annual Report for 2021

March 24, 2022

Outcome in AlzeCure’s rights issue

March 22, 2022

AlzeCure gets two NeuroRestore abstracts accepted to Alzheimer’s conference

March 21, 2022

AlzeCure presents new preclinical Alzstatin data at Alzheimer conference

March 17, 2022

AlzeCure presents new data at AD/PD meeting on NeuroRestore’s positive effect on mitochondrial function

March 15, 2022

AlzeCure presents new clinical data with ACD856 at Alzheimer’s conference

March 10, 2022

AlzeCure presents at BioStock Investor Meeting on March 16

March 8, 2022

AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease

March 4, 2022

AlzeCure Pharma AB publishes prospectus and invites to investor presentations

February 24, 2022

AlzeCure publishes its Year-end report for 2021

February 10, 2022

AlzeCure intends to carry out a rights issue of approximately SEK 60.4 million

February 8, 2022

AlzeCure is moving towards Phase IIa clinical trial with ACD440 based on guiding response from the FDA

January 27, 2022

Novel data in Alzstatin Alzheimer’s project presented at the 11th Pharmaceutical Profiling meeting

January 18, 2022

AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference

January 12, 2022

AlzeCure holds a digital Capital Markets Day on 18 January

January 11, 2022

AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function

January 4, 2022

AlzeCure presents novel Alzstatin data at the 11th Pharmaceutical Profiling meeting

Share
  • Media
    • Press releases
    • Presentations and Interviews
    • Video gallery
    • Image bank
      • Board of directors
      • Management
      • Founders
      • Logotype
    • Financial calendar
    • Subscribe
    • Contact
Mikael Widell
Mikael Widell
Head of Communications and IR
mikael.widell@alzecurepharma.com
+46 703 11 99 60
About us
  • AlzeCure Pharma in brief
  • Mission, Vision & Strategy
  • A word from the CEO
  • Organization
  • Career
  • History
Research & development
  • Project portfolio
  • NeuroRestore
  • Alzstatin
  • Alzheimer’s disease
  • Painless
  • Pain
  • Small molecules
  • Publications
Governance
  • Corporate Governance Reports
  • General meeting
  • Nomination Committee
  • Board of directors
  • Management team
  • Remuneration
  • Auditors
  • Articles of association
Investors
  • Rights Issue 2022
  • AlzeCure Pharma on First North Premier Growth Market
  • The share
  • Financial reports
  • Financial calendar
  • Presentations and Interviews
  • Subscribe
  • Contact
Media
  • Press releases
  • Presentations and Interviews
  • Video gallery
  • Image bank
  • Financial calendar
  • Subscribe
  • Contact
Contact
  • Office
  • Investors
  • Media

AlzeCure Pharma AB, Hälsovägen 7,  SE-141 57 Huddinge, Sweden. Registration number: 559094-8302.

  • Follow us on LinkedIn
  • About cookies
  • Privacy policy for Alzecure Pharma